Pioglitazone and Quetiapine XR Pharmacogenetic Study

Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.

Inclusion Criteria:

• Must have participated in IRB protocols 10-06-19, 12-07-29, 07-07-20, and 07-08-24
• Patient must give consent to participate, sign and date the IRB approved written informed consent form prior to the initiation of any procedures for this study
• Patient must be diagnosed with Bipolar Disorder or Major Depressive Disorder
• Patient must be at least 18 years old
• Patient must be willing to give a blood sample

Exclusion Criteria:

• Patient lacks the capacity to provide informed consent